Another direct NLRP3 inhibitor, CY-09, was evaluated alone or in combination with sleeve gastroplasty in MASLD mouse models.157,158 Treatment with CY-09 ameliorated obesity, insulin resistance and hepatic steatosis in mice fed a HFD.157,158 Further pre-clinical evaluation of CY-09 mechanisms in the setting of MASH seems warranted. The gene discussed is NLRP3; the disease is Hepatic steatosis.